AJ13--Pharmarcokinetics for Experimental Rheumatoid Arthritis treatment
| Location: | Federal |
|---|---|
| Posted: | Jul 16, 2026 |
| Due: | Jul 31, 2026 |
| Agency: | VETERANS AFFAIRS, DEPARTMENT OF |
| Type of Government: | Federal |
| Category: |
|
| Solicitation No: | 36C24526Q0669 |
| Publication URL: | To access bid details, please log in. |
Follow
Active
Contract Opportunity
Notice ID
36C24526Q0669
Related Notice
36C24526Q0669
Department/Ind. Agency
VETERANS AFFAIRS, DEPARTMENT OF
Sub-tier
VETERANS AFFAIRS, DEPARTMENT OF
Office
245-NETWORK CONTRACT OFFICE 5 (36C245)
Looking for contract opportunity help?
APEX Accelerators are an official government contracting resource for small businesses. Find your local APEX Accelerator (opens in new window) for free government expertise related to contract opportunities.
APEX Accelerators are funded in part through a cooperative agreement with the Department of Defense.
The APEX Accelerators program was formerly known as the Procurement Technical Assistance Program (opens in new window) (PTAP).
- Contract Opportunity Type: Presolicitation (Original)
- Original Published Date: Jul 16, 2026 07:40 am EDT
- Original Response Date: Jul 31, 2026 09:00 am EDT
- Inactive Policy: Manual
- Original Inactive Date: Sep 29, 2026
-
Initiative:
- None
- Original Set Aside:
- Product Service Code: AJ13 - GENERAL SCIENCE & TECHNOLOGY R&D SVCS; GENERAL SCIENCE & TECHNOLOGY; EXPERIMENTAL DEVELOPMENT
-
NAICS Code:
- 112990 - All Other Animal Production
-
Place of Performance:
Contractor's Lab/Facility See Sources Sought Notice for Details , 21218USA
PRE SOLICITATION NOTICE
Department of Veterans Affairs Network Contracting Office (NCO) 05
Title: A Joint Targeted Drug Delivery Approach for Arthritis Therapy Toxicity and Pharmacokinetics
The Department of Veterans Affairs (VA), Network Contracting Office (NCO) 05, intends to issue a solicitation for preclinical toxicology and pharmacokinetic (PK) studies to support advancement of an experimental joint targeted liposomal delivery system for Rheumatoid Arthritis therapy. This requirement involves GLP compliant toxicity studies and GLP or non GLP PK studies in adult rats.
The forthcoming solicitation will seek a contractor capable of performing:
GLP single dose IV toxicity studies including clinical observations, weight/food intake monitoring, blood chemistry assessments, necropsy, and histopathology.
GLP or non GLP pharmacokinetic studies including IV dosing, timed blood collection, plasma processing and storage, LC MS/MS analysis of dexamethasone and 6 hydroxydexamethasone, and calculation of PK parameters.
A comprehensive final written report covering toxicity results, PK data, and analytical findings.
Place of performance will be the contractor s laboratory. The anticipated period of performance is one year, approximately September 15, 2026 through September 14, 2027.
This notice is issued solely for informational purposes. A formal solicitation and the Government s acquisition strategy will be issued after completion of market research.
This notice does not constitute a solicitation and does not commit the Government to award a contract.
Point of Contact:
Robert O Keefe Jr., Contract Specialist
Email: robert.okeefejr@va.gov
Department of Veterans Affairs Network Contracting Office (NCO) 05
Title: A Joint Targeted Drug Delivery Approach for Arthritis Therapy Toxicity and Pharmacokinetics
The Department of Veterans Affairs (VA), Network Contracting Office (NCO) 05, intends to issue a solicitation for preclinical toxicology and pharmacokinetic (PK) studies to support advancement of an experimental joint targeted liposomal delivery system for Rheumatoid Arthritis therapy. This requirement involves GLP compliant toxicity studies and GLP or non GLP PK studies in adult rats.
The forthcoming solicitation will seek a contractor capable of performing:
GLP single dose IV toxicity studies including clinical observations, weight/food intake monitoring, blood chemistry assessments, necropsy, and histopathology.
GLP or non GLP pharmacokinetic studies including IV dosing, timed blood collection, plasma processing and storage, LC MS/MS analysis of dexamethasone and 6 hydroxydexamethasone, and calculation of PK parameters.
A comprehensive final written report covering toxicity results, PK data, and analytical findings.
Place of performance will be the contractor s laboratory. The anticipated period of performance is one year, approximately September 15, 2026 through September 14, 2027.
This notice is issued solely for informational purposes. A formal solicitation and the Government s acquisition strategy will be issued after completion of market research.
This notice does not constitute a solicitation and does not commit the Government to award a contract.
Point of Contact:
Robert O Keefe Jr., Contract Specialist
Email: robert.okeefejr@va.gov
Attachments/Links
Contracting Office Address
- 8849 International Drive Suite 215
- LINTHICUM , MD 21090
- USA
Primary Point of Contact
- Robert O'Keefe Jr.
- robert.okeefejr@va.gov
Secondary Point of Contact
- Jul 16, 2026 07:40 am EDTPresolicitation (Original)
- Jul 16, 2026 07:27 am EDT Sources Sought (Original)
Related Document
| Jul 16, 2026 | [Sources Sought (Original)] AJ13--Pharmarcokinetics for Experimental Rheumatoid Arthritis treatment |
Daily notification on new contract opportunities
With GovernmentContracts, you can:
- Find more opportunities and win more business
- Receive daily alerts for all new bid opportunities
- Get contract opportunities matched to your business
* Disclaimer: Information regarding bids, requests for proposals (RFPs), or requests for qualifications (RFQs) is provided on this website only for convenience and does not constitute official public notice. Persons wishing to respond to or inquire about bids, RFPs, or RFQs should contact the appropriate government department.